Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Infect Dis ; 34: 55-60, 2015 May.
Article in English | MEDLINE | ID: mdl-25748571

ABSTRACT

BACKGROUND: Prospective studies from developing countries that have investigated risk factors for trimethoprim-sulfamethoxazole (TMP-SMX)-resistant Escherichia coli in women with uncomplicated urinary tract infection (UTI) remain scarce. METHODS: Women with acute uncomplicated UTI were enrolled prospectively. Urine was sent for antimicrobial susceptibility testing. Logistic regression analysis was used to identify risk factors for TMP-SMX resistance. RESULTS: Of 405 participants, 229 (56.5%) had bacteriuria (mean age 31.9 ± 9.5 years). In the previous 12 months, 77 (33.6%) had experienced at least one UTI episode and 106 (46.3%) reported antimicrobial use. The most common uropathogens were E. coli (75.8%) and Staphylococcus saprophyticus (8.9%). For the 179 E. coli, resistance rates were highest for ampicillin (64.3%) and TMP-SMX (41.3%). Resistance to cephalosporins, nitrofurantoin, and fluoroquinolones was much lower compared with the hospital laboratory-based surveillance data. Risk factors for TMP-SMX resistance were UTI in the last 6 months (odds ratio 2.22; p = 0.04) and the number of UTI episodes in the past year (odds ratio 2.06; p = 0.004). The number of UTI episodes (adjusted odds ratio 2.21; p = 0.02) remained significant on multivariate analysis. CONCLUSIONS: TMP-SMX resistance was high. Number of previous UTI episodes was associated with increased risk of resistance; prior antimicrobial use was not. Hospital antibiograms should be used with caution when treating uncomplicated UTI.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Escherichia coli Infections/microbiology , Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology , Urinary Tract Infections/microbiology , Uropathogenic Escherichia coli/drug effects , Acute Disease , Adult , Anti-Bacterial Agents/therapeutic use , Developing Countries , Escherichia coli Infections/drug therapy , Escherichia coli Infections/epidemiology , Female , Fluoroquinolones/pharmacology , Fluoroquinolones/therapeutic use , Humans , Microbial Sensitivity Tests , Prevalence , Prospective Studies , Risk Factors , Staphylococcal Infections/epidemiology , Staphylococcus saprophyticus/drug effects , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Urinary Tract Infections/drug therapy , Urinary Tract Infections/epidemiology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...